guest ::
| Home > Publications database > Electronic health intervention to manage symptoms of immunotherapy in patients with cancer (SOFIA): Results from a randomized controlled pilot trial. > print |
| Home > Publications database > Electronic health intervention to manage symptoms of immunotherapy in patients with cancer (SOFIA): Results from a randomized controlled pilot trial. > print |
| 001 | 289215 | ||
| 005 | 20250731112213.0 | ||
| 024 | 7 | _ | |a 10.1002/cncr.35300 |2 doi |
| 024 | 7 | _ | |a pmid:38564338 |2 pmid |
| 024 | 7 | _ | |a 1934-662X |2 ISSN |
| 024 | 7 | _ | |a 0008-543X |2 ISSN |
| 024 | 7 | _ | |a 1045-7410 |2 ISSN |
| 024 | 7 | _ | |a 1097-0142 |2 ISSN |
| 024 | 7 | _ | |a 1934-6638 |2 ISSN |
| 024 | 7 | _ | |a altmetric:161516515 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-00649 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Sauer, Christina |0 0000-0003-3628-9056 |b 0 |
| 245 | _ | _ | |a Electronic health intervention to manage symptoms of immunotherapy in patients with cancer (SOFIA): Results from a randomized controlled pilot trial. |
| 260 | _ | _ | |a New York, NY |c 2024 |b Wiley-Liss |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1719832637_5815 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2024 Jul 15;130(14):2503-2514 |
| 520 | _ | _ | |a For patients receiving immune checkpoint inhibitors, early detection of immune-related adverse events (irAEs) is critical for one's safety. To this end, a smartphone app (SOFIA) was developed that featured the assessment of electronic patient-reported outcomes (ePROs) focusing on irAEs as well as a set of comprehensive supportive information. Its feasibility and preliminary efficacy were evaluated in a randomized controlled trial (RCT).Patients who received immune checkpoint inhibition therapy were randomly assigned to an intervention group (IG) or a control group (CG; care as usual). During the 12-week intervention period, IG patients used SOFIA to report twice weekly ePROs and receive cancer- and immunotherapy-relevant contents. Before a patient's next clinical visit, the physician in charge was given the ePRO reports. The primary objective was to test the feasibility of SOFIA. Furthermore, the preliminary efficacy of SOFIA for health-related quality of life (HRQOL), psychosocial outcomes, and medical data was examined. Clinical outcomes were assessed at baseline (T0), post-intervention (T1), and a 3-month follow-up (T2).Seventy-one patients were randomized to the IG (n = 34) or the CG (n = 37). SOFIA showed high feasibility and acceptance. At T1, patients in the IG reported significantly better HRQOL and role functioning and less depression, distress, and appetite loss. No significant differences were revealed regarding medical data, the utilization of supportive care services, or survival.SOFIA showed high feasibility and acceptance and improved HRQOL and psychosocial outcomes. These results suggest further evaluation of efficacy in a large-scale confirmatory multicenter RCT. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a cancer |2 Other |
| 650 | _ | 7 | |a electronic health (eHealth) |2 Other |
| 650 | _ | 7 | |a electronic patient‐reported outcomes (ePROs) |2 Other |
| 650 | _ | 7 | |a immunotherapy |2 Other |
| 650 | _ | 7 | |a mobile health (mHealth) |2 Other |
| 650 | _ | 7 | |a psycho‐oncology |2 Other |
| 700 | 1 | _ | |a Zschäbitz, Stefanie |b 1 |
| 700 | 1 | _ | |a Krauss, Jürgen |b 2 |
| 700 | 1 | _ | |a Walle, Thomas |0 P:(DE-He78)51635089578f68fc9efdb61e6a760b64 |b 3 |u dkfz |
| 700 | 1 | _ | |a Haag, Georg Martin |0 P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d |b 4 |u dkfz |
| 700 | 1 | _ | |a Jäger, Dirk |0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |b 5 |u dkfz |
| 700 | 1 | _ | |a Hiller, Kiriaki |b 6 |
| 700 | 1 | _ | |a Bugaj, Till Johannes |b 7 |
| 700 | 1 | _ | |a Friederich, Hans-Christoph |b 8 |
| 700 | 1 | _ | |a Maatouk, Imad |b 9 |
| 773 | _ | _ | |a 10.1002/cncr.35300 |g p. cncr.35300 |0 PERI:(DE-600)1479932-7 |n 14 |p 2503-2514 |t Cancer |v 130 |y 2024 |x 0008-543X |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/289215/files/Cancer%20-%202024%20-%20Sauer%20-%20Electronic%20health%20intervention%20to%20manage%20symptoms%20of%20immunotherapy%20in%20patients%20with%20cancer%20SOFIA%20.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/289215/files/Cancer%20-%202024%20-%20Sauer%20-%20Electronic%20health%20intervention%20to%20manage%20symptoms%20of%20immunotherapy%20in%20patients%20with%20cancer%20SOFIA%20.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:289215 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)51635089578f68fc9efdb61e6a760b64 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER-AM CANCER SOC : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCER-AM CANCER SOC : 2022 |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)F230-20160331 |k F230 |l KKE Virotherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D490-20160331 |k D490 |l KKE Virotherapie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l D120 Angewandte Tumor-Immunität |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F230-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D490-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|